FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation (Q26853282)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation |
scientific article |
Statements
1 reference